David Fredrickson
EVP, Oncology Business UnitAstraZeneca
PharmaceuticalsView Profile →President, Biomedical Research · Novartis
Fiona H. Marshall is Novartis’s president of Biomedical Research. Her scientific leadership spans GSK, Millennium, the founding of Heptares and discovery and translational research at Merck.
Last reviewed: Nov 15, 2026
Fiona H. Marshall is Novartis’s president of Biomedical Research. Her scientific leadership spans GSK, Millennium, the founding of Heptares and discovery and translational research at Merck.
Marshall studied biochemistry at Bath and completed a neuroscience doctorate at Cambridge. Early in her career she spent a decade at GSK in molecular pharmacology and neuroscience, and later directed molecular pharmacology at Millennium Pharmaceuticals.
In 2006 she founded Heptares Therapeutics, becoming chief scientific officer of the structure-based drug-design company. She also served as executive vice president and chief scientific officer of Sosei Heptares from 2015 to 2018.
She joined Merck in 2018 to head UK discovery research, moved to global neuroscience leadership in 2019, and became senior vice president for discovery, preclinical and translational medicine in 2021.
Marshall became Novartis’s president of Biomedical Research in November 2022. Her scientific recognition includes fellowship of the Royal Society and the Academy of Medical Sciences, the Royal Society of Chemistry’s Malcolm Campbell Award, and the British Pharmacological Society’s Vane Medal.
Doctorate — University of Cambridge — Neuroscience.
Bachelor’s degree — University of Bath — Biochemistry.